Eli Lilly Japan Helps Students Through Emotional Disorder Educational Programs
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly Japan, along with other companies, has helped the Japanese nonprofit organization Association of Corporations and Education develop an educational program on emotional disorders targeting junior high and senior high school students. The development of the program also received advice and input from psychiatrists and patients. Pilot classes of the program were conducted at the end of November. Since then, the program has received accolades from experts in the field. Professor Mizuno of Toho University, a psychiatrist, states that from the point of early discovery and early treatment, teaching the program to junior and high school students who are prone to develop emotional disorders will be useful. The final compilation of materials for the program, including PowerPoint slides, DVD videos, teacher's manuals and videos of pilot classes, is scheduled to be completed by the middle of January. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.